Clinical trial registry record

Clinical Study Of Pegaptanib Sodium (EYE001) For Wet-Type Age-Related Macular Degeneration

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Completed.
Evidence
Registered phase 2 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated May 12, 2011.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT00239928
Last registry update
May 12, 2011
Status
Completed
Phase
Phase 2
Sponsor
Pfizer
Enrollment
61
Countries
Japan
Match confidence
100%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 2
Study design
NON RANDOMIZED · SINGLE GROUP · TREATMENT · NONE
Evidence population
Human clinical study registration
Participants
61
Population
ALL · 51 Years
Duration
2005-09-01 to 2008-11-01
Intervention
pegaptanib sodium
Comparator
Not reported
Outcomes measured
Summary of Adverse Events — Week 54 (initiation of A5751015 study) up to Week 198; Mean Change in Visual Acuity From Baseline of A5751010 (NCT00150202) to Each Observation Time Point — Week 0 (baseline)…; Mean Change in Visual Acuity From the Starting Point of Current Study to Each Observation Time Point — Weeks 54, every…; Number of Responders — Week 0 (baseline), every 18 weeks from Week 54 up to Week 198; Number of Subjects Gaining Vision From Baseline of A5751010 (NCT00150202) — Week 0 (baseline), every 18 weeks from Week…; Number of Subjects Who Are Maintaining Vision From Baseline of A5751010 (NCT 00150202) — Week 0 (baseline), every 18 we…; Number of Subjects With Severe Vision Loss From Baseline of A5751010 (NCT 00150202) — Week 0 (baseline), every 18 weeks…
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 2A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 100% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Vision ageing · 100%Title contains controlled topic terminology. Summary contains controlled topic terminology. Title supplies ageing or longevity context.

Automated source check 100% · update recency 35%. These figures help sort records; they are not medical ratings.

vision aging
Read the original source →Export JSON